QIAGEN and Natera partner to develop cutting-edge genetic testing assays for use on QIAGEN’s GeneReader NGS System

MAR 12 2018 Hilden, Germany, and San Carlos, CA, March 12, 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA), a world leader in providing Sample to Insight molecular solutions, and Natera, Inc. (NASDAQ: NTRA), a leading developer of next-generation sequencing (NGS) assays that include non-invasive prenatal genetic testing and the analysis of circulating tumor... Read more